

Originally founded in 2011 Cordack's CMC and formulation expertise has speeded and derisked drug development adding value to many organizations:

Startups

CMC leadership, initiation, lead selection through phase I, strategy, early project management and execution including contractor identification engagement and management

Small pharma

CMC leadership, strategy, formulation and project management & execution through phase III, including contractor engagement and management

Multinationals

Due diligence and CMC strategy & execution through commercial including contractor engagement and management

Investors

Strategy and due diligence

Contract Services

Business strategy, operational efficiency, BD and sales & marketing

Colin Minchom PhD

Founder and
Principal CMC Consultant

LinkedIn [Colin Minchom](#)



Experience

With extensive experience in drug development, organizations and CMC, Colin Minchom advises, project manages, and executes on CMC formulation & drug delivery strategy and development for companies at all stages in the development continuum; mitigating risk and facilitating cost & time effective development pathways.

Previously at [Shire](#) as the CMC lead for two priority programs, he was also the head of CMC Due Diligence for synthetic molecules.

Dr. Minchom worked in contract services for fourteen years including holding executive leadership positions at [Patheon](#) latterly leading development in North America and [Hovione](#) where he led the teams improving bioavailability of poorly soluble molecules. He previously worked at [Eli Lilly](#) at the discovery/development interface, and also a UK startup.

Colin Minchom is a life science mentor at [MassCONNECT](#), the [Massachusetts Biotechnology Council](#) entrepreneur mentorship program. He was a drug development advisor at [MaRS](#), a Toronto medical science incubator, where he lectured on [drug product development best practices for startups](#). Dr. Minchom is active in the [American Association of Pharmaceutical Scientists](#), having chaired the 25th anniversary AAPS annual meeting.

Colin Minchom sits on a General Chapters Expert Committee for the [USP](#), lectures at Harvard Medical School, and presented at an MIT conference on enabling drug delivery technologies.

Dr. Minchom received his PhD in Industrial Pharmacy from the University of Wales, UK and is a Fellow of the Royal Pharmaceutical Society of Great Britain.

Notable successes

Speedy and cost-effective development of several phase I, II and III product programs to meet aggressive timelines, using both internal assets and managing CDMOs.

The identification and engagement of a CDMO to develop and commercially manufacture a high ethanol concentration companion animal product.

Successful negotiation with FDA to enable a path forward, despite chemical stability issues, for initiation of phase III studies of an oral liquid suspension.

Significant contributions to the approval and commercialization of thirteen drug products in the US, EU and Japan.

Strategy development for a startup CDMO enabling fast growth in a competitive market.

M&A and licensing due diligence enabling the acquisition of two ophthalmic and one GI pharmaceutical asset.

Contact

Cordack LLC, Arlington MA, USA
Telephone: +1 609 436 0087
colin.minchom@cordack.com
www.cordack.com

CORDACK ... value proposition

